Ensysce Biosciences (NASDAQ:ENSC) Releases Earnings Results, Beats Expectations By $0.17 EPS

Ensysce Biosciences (NASDAQ:ENSC) posted its quarterly earnings results on Monday. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.17, reports. Ensysce Biosciences had a negative return on equity of 437.31% and a negative net margin of 244.47%.The company had revenue of $1.88 million for the quarter, compared to analysts’ expectations of $0.50 million.

Ensysce Biosciences Trading Down 2.6%

Shares of ENSC traded down $0.01 during trading hours on Monday, reaching $0.51. The company had a trading volume of 184,068 shares, compared to its average volume of 6,204,540. Ensysce Biosciences has a 12-month low of $0.31 and a 12-month high of $4.85. The firm has a 50 day simple moving average of $0.57 and a 200-day simple moving average of $1.35. The company has a market capitalization of $1.87 million, a price-to-earnings ratio of -0.08 and a beta of 1.14.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENSC. Virtu Financial LLC acquired a new position in shares of Ensysce Biosciences during the 3rd quarter worth approximately $34,000. Citadel Advisors LLC acquired a new stake in Ensysce Biosciences during the 3rd quarter valued at $34,000. DRW Securities LLC increased its position in Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after buying an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after buying an additional 75,000 shares in the last quarter. 5.63% of the stock is currently owned by institutional investors and hedge funds.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.